#Gene Synthesis Market
Explore tagged Tumblr posts
sheetalblogs · 4 months ago
Text
0 notes
geethasingh · 1 year ago
Text
0 notes
marketspace360 · 2 years ago
Text
Gene Synthesis Market| Manufacturers, Regions, Type and Application, Forecast by 2029
Tumblr media
0 notes
global-research-report · 5 days ago
Text
The Future of Gene Synthesis: Market Analysis and Key Insights
The global gene synthesis market size is expected to reach USD 5.78 billion by 2030, registering a CAGR of 16.1% from 2023 to 2030 according to a new report by Grand View Research, Inc. Development of the market is due  to the growing investment in the synthetic biology field, favorable government regulations, and technological advancements in the gene synthesis market. In January 2022, synthetic DNA manufacturer Twist Bioscience announced plans of developing EDS technology at the J.P. Morgan Health Care Conference. The company established an enzymatic DNA synthesis technology that is novel, low-cost, scarless, and scalable.
The introduction of novel DNA synthesis platforms with technologically advanced specifications that address the increased demand of researchers is also contributing to the overall growth. For instance, in June 2021, DNA Script introduced the SYNTAX System, which is the nucleic acid printer based on EDS technology. Similarly, in December 2020, Evonetix Ltd. entered into a research collaboration with Analog Devices, Inc. Under the terms of the agreement, the companies collaborated on Evonetix's Microelectromechanical System-based silicon chips' improvement and commercial scale-up, as well as the development of a DNA desktop writer.
Researchers, as well as biotechnology and pharmaceutical corporations, have become increasingly interested in targeted therapy during recent years. It has become a popular method of disease management. In the near future, targeted therapy in conjunction with chemotherapy and immunotherapy is likely to develop significantly, presenting lucrative prospects for both emerging & established competitors in the gene synthesis market.
Key players are focusing on product development and are entering into partnerships and collaborations to expand their product offerings. For instance, In January 2022, Thermo Fisher Scientific, Inc. completed the acquisition of PeproTech, Inc.- a producer of antibodies and vectors. This acquisition may help the company strengthen its position in the market. Similarly, in July 2021, GenScript hosted the GenScript Gene & Cell Engineering Virtual Summit. This event focused on highlighting synthetic biology research to enhance protein design, drug discovery, and genome editing, enabling the company to increase its customer base.
Gene Synthesis Market Report Highlights
The growth is attributed to the growing demand for the synthetic biology, coupled with increasing government support to offer funds for R&D initiatives in synthetic biology
By method, solid-phase synthesis dominated in 2022 as it offers high accuracy and is a prominent technology for the applications in several fields and for various research purposes
By services, antibody DNA synthesis dominated the gene synthesis market in 2022, owing to the presence of significant players such as Synbio offers services, Twist Bioscience Corporation, and others, offering services in this segment
By application, the gene & cell therapy development segment dominated the gene synthesis market in 2022. This is attributed to the growing number of R&D programs for the development of cell and gene therapies
By end-use, academic and government research institute dominated the gene synthesis market in 2022, as most of the gene synthesis process is performed in the research settings for clinical research and investigational programs
North America captured the highest share in 2022 owing to the well-established molecular biology infrastructure along with the presence of a significant number of market players in the region
Gene Synthesis Market Segmentation
Grand View Research has segmented the global gene synthesis market report based on the method, services, application, end-use, and region:
Gene Synthesis Method Outlook (Revenue, USD Million, 2018 - 2030)
Solid-phase Synthesis
Chip-based Synthesis
PCR-based Enzyme Synthesis
Gene Synthesis Services Outlook (Revenue, USD Million, 2018 - 2030)
Antibody DNA Synthesis
Viral DNA Synthesis
Others
Gene Synthesis Application Outlook (Revenue, USD Million, 2018 - 2030)
Gene & Cell Therapy Development
Vaccine Development
Disease Diagnosis
Others
Gene Synthesis End-use Outlook (Revenue, USD Million, 2018 - 2030)
Biotechnology & Pharmaceutical Companies
Academic & Government Research Institutes
Contract Research Organizations
Gene Synthesis Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
US
Canada
Europe
Germany
UK
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
China
India
Japan
South Korea
Australia
Thailand
Latin America
Brazil
Mexico
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
Key Players
GenScript
Brooks Automation, Inc. (GENEWIZ)
Boster Biological Technology
Twist Bioscience
ProteoGenix, Inc
Biomatik
ProMab Biotechnologies, Inc.
Thermo Fisher Scientific, Inc.
Integrated DNA Technologies, Inc.
OriGene Technologies, Inc.
Order a free sample PDF of the Gene Synthesis Market Intelligence Study, published by Grand View Research.
0 notes
industry24 · 1 month ago
Text
0 notes
market-insider · 2 years ago
Text
Gene Synthesis in Therapeutics and Biopharmaceuticals: Market Trends and Growth Outlook
Gene synthesis refers to the artificial construction of genes using chemical synthesis methods, rather than relying on natural DNA replication processes. It involves assembling nucleotides, the building blocks of DNA, in a specific order to create a desired gene sequence. Gene synthesis has become a powerful tool in molecular biology and biotechnology, enabling scientists to design and engineer genes with precise sequences for various applications. In gene synthesis, the desired gene sequence is typically designed on a computer using bioinformatics tools. The designed sequence may include modifications, such as codon optimization, to enhance gene expression in specific organisms. Once the gene sequence is finalized, it is divided into shorter fragments, typically around 100-200 base pairs in length, for synthesis.
Tumblr media
Gain deeper insights on the market and receive your free copy with TOC now @: Gene Synthesis Market Report
Gene synthesis can be achieved through various methods, including solid-phase DNA synthesis and enzymatic assembly. Solid-phase DNA synthesis involves adding nucleotides one-by-one to a growing DNA strand attached to a solid support. Enzymatic assembly methods utilize enzymes, such as DNA polymerases and ligases, to join the shorter DNA fragments together to form the complete gene sequence. After synthesis, the gene sequence can be inserted into a vector, which is a DNA molecule that can be propagated in host cells, for further cloning and manipulation. Gene synthesis has wide-ranging applications, including genetic engineering, synthetic biology, protein production, vaccine development, and gene therapy.
The advancements in gene synthesis technologies have made it more accessible and affordable, allowing researchers to create custom-designed genes for their specific research needs. Gene synthesis has also contributed to the rapid progress in fields such as synthetic biology, where complex gene circuits and novel biological systems can be constructed to perform specific functions. Overall, gene synthesis has revolutionized genetic research and biotechnology by providing a means to engineer and manipulate DNA sequences with precision and versatility.
Gene synthesis companies have been scaling up their operations to meet the growing demand for synthetic DNA. This includes the establishment of larger synthesis facilities and the utilization of high-throughput platforms, allowing for the parallel synthesis of multiple genes or larger gene constructs. The cost of gene synthesis has been decreasing over the years, making it more accessible to a wider range of researchers and industries. Advances in synthesis methods, automation, and economies of scale have contributed to cost reductions, enabling more affordable gene synthesis services. Codon optimization, the process of modifying gene sequences to optimize expression in specific host organisms, has become more sophisticated. Gene synthesis providers offer improved algorithms and tools for codon optimization, enabling the design of genes with enhanced expression levels and improved protein production. Additionally, the integration of gene editing technologies, such as CRISPR-Cas9, into gene synthesis workflows has opened up new possibilities for precise genetic modifications and genome engineering.
Many gene synthesis companies have developed user-friendly online platforms that allow researchers to easily submit gene synthesis orders and customize their desired gene sequences. These platforms often provide real-time pricing, design tools, and support for various modifications, including site-directed mutagenesis, fusion proteins, and reporter tags. Quality control measures in gene synthesis have improved, ensuring the accuracy and integrity of synthesized gene sequences. Companies employ rigorous verification processes, including DNA sequencing, to confirm the fidelity of synthesized genes. Some providers also offer additional quality control options, such as mass spectrometry-based analysis and functional testing. The application areas for gene synthesis continue to expand. Besides traditional research applications, gene synthesis is increasingly utilized in industrial biotechnology, pharmaceutical development, agricultural biotechnology, and gene therapy. The ability to engineer custom DNA sequences has facilitated the development of new bio-based products, therapeutic modalities, and improved crop traits.
0 notes
metastatblog · 4 days ago
Text
Biopharmaceuticals Market Analysis, Size, Share, Growth, Trends, and Forecasts by 2031
Tumblr media
In the expansive landscape of the pharmaceutical industry, one of its most dynamic sectors is the Global Biopharmaceuticals market. Unlike traditional pharmaceuticals derived from chemical synthesis, biopharmaceuticals are products synthesized from biological sources, such as proteins, nucleic acids, and living cells. This unique characteristic places the Global Biopharmaceuticals market at the forefront of innovation, continually pushing boundaries in the quest for novel therapeutics. 
𝐆𝐞𝐭 𝐚 𝐅𝐫𝐞𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭:https://www.metastatinsight.com/request-sample/2731
Companies
Abbvie Inc
Amgen Inc.
AstraZeneca PLC
Biogen Inc.
Bristol-Myers Squibb Company
Eli Lilly and Company
F Hoffmann-La Roche AG
GlaxoSmithKline PLC
Merck & Co., Inc.
Novartis AG
Novo Nordisk A/S
Pfizer Inc.
Sanofi SA
Takeda Pharmaceutical Company Limited
Abbott
T𝐡𝐞 𝐅𝐮𝐥𝐥 𝐑𝐞𝐩𝐨𝐫𝐭:@https://www.metastatinsight.com/report/biopharmaceuticals-market
The industry of Global Biopharmaceuticals is driven by a relentless pursuit of groundbreaking treatments for a myriad of diseases and medical conditions. With advancements in biotechnology and molecular biology, researchers and scientists are empowered to explore new avenues for drug development, harnessing the power of living organisms to create targeted and effective therapies. 
Within the Global Biopharmaceuticals, a diverse array of products emerges, ranging from monoclonal antibodies and vaccines to gene and cell therapies. These products hold immense promise in revolutionizing healthcare, offering personalized treatments tailored to individual patients’ genetic makeup and disease profiles. 
The Global Biopharmaceuticals market is characterized by intense competition and rapid innovation. As technology evolves and scientific knowledge expands, new players enter the market, challenging established giants and fueling a cycle of continuous improvement and discovery. This environment fosters collaboration among industry stakeholders, including pharmaceutical companies, research institutions, and regulatory bodies, driving collective efforts towards advancing medical science and improving patient outcomes. 
The Global Biopharmaceuticals market represents a dynamic and ever-evolving industry at the forefront of scientific innovation and medical progress. With its diverse portfolio of products, collaborative ecosystem, and global reach, it is poised to shape the future of healthcare and redefine the way we approach disease treatment and management. As we embark on this journey of discovery and transformation, the potential for groundbreaking advancements and life-changing therapies is limitless. 
Global Biopharmaceuticals market is estimated to reach $1,138,538.5 Million by 2031; growing at a CAGR of 13.8% from 2024 to 2031.
Contact Us:   
+1 214 613 5758
0 notes
skyquest-market-research · 5 days ago
Text
Oligonucleotide Synthesis Market Outlook, Size, Growth Factors, and Forecast 2025-2032
Tumblr media
Oligonucleotide synthesis market is experiencing rapid expansion, driven by increasing applications in genetic research, diagnostics, therapeutics, and drug discovery. As advancements in synthetic biology and molecular diagnostics continue to evolve, the demand for high-quality oligonucleotides is soaring. According to SkyQuest’s latest report on the Oligonucleotide Synthesis Market, Oligonucleotide Synthesis Market size is poised to grow at a CAGR of 17.4% by 2032, driven by technological innovations and rising research investments.
The oligonucleotide synthesis market plays a crucial role in genomics, molecular biology, and biotechnology. It encompasses the development of short DNA and RNA sequences that serve as essential tools for PCR, gene editing, and targeted therapeutics. With the increasing adoption of oligonucleotides in clinical applications, the market is projected to experience significant expansion in the coming years.
Request a sample of the report here: https://www.skyquestt.com/sample-request/oligonucleotide-synthesis-market
Key Market Drivers Shaping Oligonucleotide Synthesis Growth
Growing Demand for Personalized Medicine
The rise of precision medicine has fueled the demand for custom oligonucleotides. Researchers and pharmaceutical companies are increasingly leveraging oligonucleotides for targeted therapies, particularly in cancer treatment and rare genetic disorders.
Advancements in Gene Editing Technologies
Innovations in CRISPR, RNA interference (RNAi), and antisense oligonucleotides are expanding the scope of oligonucleotide-based therapies. These breakthroughs are transforming genetic research, enabling more precise and effective treatments.
Expanding Applications in Diagnostics
Oligonucleotide probes and primers are widely used in molecular diagnostics, particularly in PCR-based testing, next-generation sequencing (NGS), and microarrays. The increasing prevalence of infectious diseases and genetic disorders has driven the demand for oligonucleotide-based diagnostic solutions.
Increased Investment in Biotechnology Research
Pharmaceutical and biotech companies are investing heavily in oligonucleotide research, aiming to develop novel therapeutics and drug delivery mechanisms. Governments and private organizations are also providing funding to accelerate genetic research.
Speak with an analyst for in-depth market insights: https://www.skyquestt.com/speak-with-analyst/oligonucleotide-synthesis-market
Oligonucleotide Synthesis Market Segmentation:
By Product Type
Synthesized Oligonucleotides – Custom sequences used in research, diagnostics, and therapeutics
Reagents and Consumables – Essential materials for synthesis processes
Equipment – Automated synthesizers and analytical tools for high-throughput oligonucleotide production
By Application
Research & Development – Genomic studies, drug discovery, and synthetic biology
Diagnostics – PCR, NGS, and DNA microarrays
Therapeutics – Antisense oligonucleotides, siRNA, and mRNA-based therapies
By End-User
Biotechnology & Pharmaceutical Companies – Focused on drug development and clinical applications
Academic & Research Institutions – Conducting genomics and molecular biology studies
Contract Research Organizations (CROs) – Supporting large-scale oligonucleotide synthesis and testing
Oligonucleotide Synthesis Market Regional Insights
North America: Leading the Market with Strong Research Infrastructure
The United States and Canada dominate the oligonucleotide synthesis market, driven by strong research capabilities, robust funding, and a high concentration of biotechnology companies. The presence of key industry players and increasing clinical trials further contribute to regional growth.
Europe: Rising Investments in Genetic Research
Countries like Germany, the UK, and France are expanding their biotechnology sectors, investing in advanced gene therapy and diagnostic solutions. The European Union’s support for genomic research is fostering innovation in oligonucleotide applications.
Asia-Pacific: Fastest-Growing Market with Expanding Biotech Industry
China, Japan, and India are witnessing rapid market expansion due to increasing investments in genetic research, a growing pharmaceutical industry, and government support for biotechnological advancements. The demand for oligonucleotide-based diagnostics and therapies is significantly increasing in the region.
Latin America & Middle East: Emerging Markets with High Growth Potential
Countries in Latin America and the Middle East are gradually adopting oligonucleotide synthesis technologies, primarily in medical research and infectious disease diagnostics. Increasing healthcare investments are expected to drive market growth in these regions.
Buy the full report for comprehensive market analysis: https://www.skyquestt.com/buy-now/oligonucleotide-synthesis-market
Key Players in the Oligonucleotide Synthesis Market
Several major players dominate the oligonucleotide synthesis market, focusing on innovation, product development, and strategic collaborations. Key companies include:
Thermo Fisher Scientific
Agilent Technologies
Merck KGaA
Integrated DNA Technologies (IDT)
LGC Biosearch Technologies
Eurofins Genomics
GenScript Biotech Corporation
TriLink BioTechnologies
These companies are expanding their production capacities and investing in new technologies to meet the rising demand for synthetic oligonucleotides.
Emerging Trends and Technological Innovations
Automated High-Throughput Synthesis
The adoption of automated systems is improving efficiency, scalability, and precision in oligonucleotide production. Advanced synthesis platforms are enabling rapid turnaround times for research and clinical applications.
Expansion of RNA-Based Therapeutics
RNA-based drugs, including mRNA vaccines and RNAi therapies, are gaining significant traction. This trend is expected to drive the demand for oligonucleotide synthesis in pharmaceutical and biotech industries.
Sustainable and Cost-Effective Synthesis Methods
Researchers are developing green synthesis approaches to minimize environmental impact and reduce production costs, making oligonucleotide synthesis more sustainable.
The Future of the Oligonucleotide Synthesis Market
The oligonucleotide synthesis market is on an upward trajectory, driven by advancements in gene editing, diagnostics, and therapeutics. As personalized medicine gains momentum and biotechnology continues to evolve, the demand for high-quality oligonucleotides will continue to rise. Companies investing in automation, innovative research, and sustainable production methods are well-positioned for success in this rapidly growing industry.
For a detailed market analysis and strategic insights, explore the full SkyQuest report: https://www.skyquestt.com/report/oligonucleotide-synthesis-market
0 notes
industryforecastnews · 5 days ago
Text
Synthetic Biology Market Size, Share And Trends Report, 2030
Tumblr media
Synthetic Biology Market Growth & Trends
The global synthetic biology market size is expected to reach USD 42.06 billion by 2030, registering a CAGR of 17.30% 2025 to 2030, according to a new report by Grand View Research, Inc. The presence of government and private funding to support research in vaccines and a strong synthetic biologic-based product pipeline in clinical trials are the key driving factors for the market. Synthetic biology processes provide crucial advantages for producing antigen and diagnostic reagents for disease identification, accelerating the speed of vaccine development, and improving overall vaccine performance and yield.
Furthermore, support from government agencies and the presence of several programs are likely to boost the market growth. For instance, in the U.S., COVID-19 vaccine R&D, manufacture, regulation, and purchase have been highly supported by collaboration between federal agencies, including the Biomedical Advanced Research and Development Authority (BARDA), the National Institutes of Health (NIH), DOD, FDA, and others (formerly OWS).
Other factors such as expanding demand in industries such as textiles and nutrition are also contributing to the market growth. Several optimal food production processes have been identified with the help of synthetic biology. In addition, synthetic biology is predicted to aid in the generation of higher agricultural yields and pest control development. It is expected to help in the production of better food yield and pest control management.
The COVID-19 pandemic is anticipated to positively impact market growth. Synthetic biology has been highlighted as a means to accelerate vaccine development by the National Institute of Health in the U.S. Therefore, synthetic biology labs and companies have been actively utilizing this technology to combat the COVID-19 pandemic. As a result, the usage of these technologies is projected to increase during the outbreak.
The growing demand for personalized medicine is expected to majorly drive market growth during the coming years. The use of engineered novel proteins for use as therapeutics has demonstrated synthetic biology in the medical segment. These proteins are designed with some modified protein structure to get the desirable properties required for the treatment. For instance, researchers are developing a therapeutic enzyme candidate that is GI-stable and can be given via oral route to treat Phenylketonuria (PKU).
On the other hand, synthetic biology has raised a few concerns regarding biosecurity and biosafety. Exposure to these products may cause unknown hazards to public health and the environment. To prevent such issues, countries of Europe, the Americas, and Asia have formulated policies to manage the application of synthetic biology techniques in basic & applied research.
Request a free sample copy or view report summary: https://www.grandviewresearch.com/industry-analysis/synthetic-biology-market
Synthetic Biology Market Report Highlights
By technology, the PCR segment held the largest share of the market. This is attributed to the accelerated development in modern life science, with PCR technology being widely employed in numerous fields of medical research, virus detection, and the food & beverage industry
The genome-editing segment is expected to grow steadily during the forecast period. It enables researchers to modify the DNA of various organisms, including plants, bacteria, and animals, and their demand is expected to skyrocket in the coming years
By product, Oligonucleotide and Synthetic DNA is anticipated to have the larger market share in 2030. The falling price of synthesis and increasing requirement for synthetic DNA, RNA, and genes that are employed in numerous applications contribute to the segment growth
By application, the healthcare segment held a larger global market share. This is attributed to an increase in drug screening and discovery. Moreover, the use of synthetic biology can reduce the cost of drug discovery and propel market growth
By end-user, the biotechnology and pharmaceutical companies segment held a larger share in 2024, owing to the growing availability of modern research facilities, favorable legislation, and government assistance and funding
North America was positioned as the dominant market in 2024 due to the presence of high R&D investment, the availability of technologically advanced healthcare research frameworks, and the development of the synthetic biology market in the region
The Asia Pacific is expected to witness considerable growth in the future owing to the rising development of personalized treatment and the presence of key players
Synthetic Biology Market Segmentation
Grand View Research has segmented the global synthetic biology market based on product, technology, application, end use, and region
Synthetic Biology Product Outlook (Revenue, USD Million, 2018 - 2030)
Oligonucleotide/Oligo Pools and Synthetic DNA
Enzymes
Cloning Technologies Kits
Xeno-Nucleic Acids
Chassis Organism
Synthetic Biology Technology Outlook (Revenue, USD Million, 2018 - 2030)
NGS Technology
PCR Technology
Genome Editing Technology
Bioprocessing Technology
Other Technologies
Synthetic Biology Application Outlook (Revenue, USD Million, 2018 - 2030)
Healthcare
Non-healthcare
Synthetic Biology End Use Outlook (Revenue, USD Million, 2018 - 2030)
Biotechnology and Pharmaceutical companies
Academic and Research Institutes
Others
Synthetic Biology Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
Europe
Asia Pacific
Latin America
Middle East & Africa
List of Key Players of Synthetic Biology Market
Bota Biosciences Inc.
Codexis, Inc.
Creative Biogene.
Creative Enzymes.
Enbiotix, Inc.
Illumina, Inc.
Merck Kgaa (Sigma-Aldrich Co. Llc)
New England Biolabs
Eurofins Scientific
Novozymes
Pareto Bio, Inc.
Scarab Genomics, Llc
Synthego
Synthetic Genomics Inc.
Thermo Fisher Scientific, Inc.
Browse Full Report: https://www.grandviewresearch.com/industry-analysis/synthetic-biology-market
0 notes
anjaliavhad · 6 days ago
Text
0 notes
delveinsight12 · 22 days ago
Text
Beta-thalassemia Market Poised for Significant Growth with Novel Therapies and Rising Prevalence
The Beta-thalassemia market is set to experience remarkable growth in the coming years, driven by the increasing prevalence of the condition and the anticipated launch of innovative therapies. Leading players in the pharmaceutical and biotech industries, including Acceleron Pharma, Agios Pharmaceuticals, Bluebird Bio, and CRISPR Therapeutics, are working diligently to address unmet medical needs and expand treatment options.
Download our sample pages @ https://www.delveinsight.com/report-store/beta-thalassemia-market?utm_source=report&utm_medium=promotion&utm_campaign=kpr
Market Dynamics and Key Drivers
Beta-thalassemia, a hereditary blood disorder caused by mutations in the HBB gene, results in reduced or absent synthesis of beta-globin chains in hemoglobin. This condition affects millions worldwide, with significant prevalence in regions such as the United States, Europe, and Asia.
Recent advancements in diagnostics and a heightened focus on genetic counseling have contributed to better detection rates, thus expanding the patient pool. Improved awareness and targeted research and development efforts are fueling market expansion, with therapies such as Zynteglo (LentiGlobin BB305), Mitapivat, and Sapablursen emerging as frontrunners in the treatment landscape.
To know about the factors that are driving the beta thalassemia market forward, visit: https://www.delveinsight.com/sample-request/beta-thalassemia-market?utm_source=report&utm_medium=promotion&utm_campaign=kpr
Epidemiology Insights
DelveInsight’s comprehensive report reveals key epidemiological trends in the seven major markets (7MM), including the US, EU4 (Germany, Spain, Italy, France), the UK, and Japan:
In 2023, the United States reported approximately 1.35 million cases of Beta-thalassemia, a figure projected to grow significantly by 2034.
Italy exhibited the highest prevalence within the EU4, with 3.68 million cases in 2023, primarily comprising Beta Thalassemia Major.
Spain, with 217,000 cases of Beta Thalassemia Major, highlights the need for tailored interventions in specific regions.
These trends underscore the critical role of strategic initiatives in addressing disparities in prevalence and improving access to advanced therapies.
Marketed Therapies and Pipeline Innovations
Prominent therapies such as Reblozyl (luspatercept) and EXJADE have made significant strides in treating anemia and iron overload, respectively, in Beta-thalassemia patients. Newer drugs like betibeglogene autotemcel are poised to achieve substantial market share by 2034.
Emerging therapies are also gaining traction, with key players focusing on gene-editing technologies, single-agent molecules, and combination treatments. Companies like Editas Medicine, Beam Therapeutics, and Novartis are at the forefront of developing cutting-edge solutions.
To know about the therapies that are boosting the market, click: https://www.delveinsight.com/report-store/beta-thalassemia-market?utm_source=report&utm_medium=promotion&utm_campaign=kpr
Challenges and Opportunities
Despite notable progress, challenges persist. These include limited access to advanced therapies in certain regions, high treatment costs, and the complexity of managing Beta-thalassemia’s clinical manifestations. However, opportunities abound as collaborations between pharmaceutical companies and research organizations intensify. Strategic alliances and licensing agreements are expected to accelerate the availability of next-generation treatments.
Future Outlook
The Beta-thalassemia market is projected to grow at a substantial compound annual growth rate (CAGR) through 2034. Factors such as increased investment in R&D, robust pipeline development, and improved patient awareness will play pivotal roles in shaping the market’s trajectory.
Conclusion
With the global focus on advancing treatment options and addressing unmet needs, the Beta-thalassemia market is on the cusp of transformative growth. As new therapies gain approval and diagnostic capabilities improve, patients worldwide stand to benefit from enhanced quality of life and better disease management.
For detailed insights into market trends, emerging therapies, and the latest developments, explore DelveInsight’s comprehensive report: Beta-thalassemia (B-thal) Market Insights, Epidemiology, and Market Forecast 2034.
0 notes
neha24blog · 28 days ago
Text
Gene Synthesis Market Outlook On The Basis Of Method, Services, Application, End-Use, Region And Forecast To 2030: Grand View Research Inc.
San Francisco, 7 January 2025: The Report Gene Synthesis Market Size, Share & Trends Analysis Report By Method (Solid-phase Synthesis, Chip-based Synthesis, PCR-based Enzyme Synthesis), By Service, By Application, By End-use, By Region, And Segment Forecasts, 2023 – 2030 The global gene synthesis market size is expected to reach USD 5.78 billion by 2030, registering a CAGR of 16.1% from 2023 to…
Tumblr media
View On WordPress
0 notes
healthcaremarketanalysis · 1 month ago
Text
mRNA Synthesis & Manufacturing Market worth $738.3 million by 2029
The mRNA synthesis and manufacturing market is projected to reach USD 738.3 million in 2029 from USD 624.4 million in 2024. This market is projected to grow at a CAGR of 3.4% over the forecast period. The primary drivers behind the expansion of this industry are the Growing focus on mRNA-based vaccine development, expanding therapeutic applications of mRNA technology, advancements in mRNA synthesis technology, increased outsourcing for mRNA synthesis and modification, and collaborations among industry players. However, stability, storage, and manufacturing scalability present a challenge to this industry. This is further amplified by the slow patient adoption rate and the complexity of the development of mRNA-based therapy.
In many important respects, artificial intelligence (AI) is transforming the mRNA synthesis and manufacturing sector. First, by scanning large databases to find suitable mRNA sequences for therapeutic usage, artificial intelligence speeds up drug research and development greatly. Developed tools like the LinearDesign AI aim to maximize mRNA sequences, therefore producing vaccines with more antibody responses than conventional techniques. From raw material acquisition to final product packaging, artificial intelligence maximizes several manufacturing steps, thereby lowering costs and raising efficiency. AI-powered predictive maintenance reduces downtime and guarantees manufacturing equipment's seamless running.
Download PDF Brochure:
Browse in-depth TOC on "mRNA Synthesis & Manufacturing Market"
250 - Tables
50 - Figures
250 - Pages
The market is expanding rapidly due to factors such as the development of mRNA-based vaccines and expanded applications such as cancer immunotherapies. Furthermore, improvements in mRNA synthesis technology, a rise in mRNA synthesis and modification outsourcing, and industry players working together to create mRNA therapies all contribute to the growth of the mRNA synthesis and manufacturing market. Additionally, factors such as advancements in drug delivery technologies, growth in the regenerative medicines market, and increasing government funding and private investments in the mRNA therapeutics market will further provide revenue growth opportunities for the players operating in mRNA synthesis & manufacturing.
Based on product type, the mRNA synthesis and manufacturing products market is divided into two broad categories, consumables and instruments. The consumables segment of the market held the largest market share in 2023, due to the sustained use of consumables such as nucleotides, RNA polymerase, reverse transcriptase, buffer, and reagents that also require frequent repurchases. The consumables segment will be experiencing high growth due to several factors, including an increase in the mRNA therapeutics pipeline and growing investments made to develop mRNA-based therapeutics, advancement in mRNA synthesis technologies, increase in demand for consumables among contract service providers with the growing trend of outsourcing.
Based on service type, the global mRNA synthesis and manufacturing services market has been categorized into four service types: mRNA synthesis, modification, and related activities; purification of mRNA; analytical and characterization services; and scale-up and manufacture activities. In 2023, the mRNA synthesis and modification services captured the highest market share because of the demand for custom and modified mRNA sequences, which are intended to enhance therapeutic candidates for the molecules market. Given the expanding uses of the mRNA technology, researchers and developers are looking for mRNA sequences that can incorporate protein expression enhancement or immune response improvement.
Based on application, the market for mRNA synthesis and manufacturing has been divided into segments including vaccines and cell & gene therapy. The vaccine segment has the dominant share in the market in 2023. The large share of this segment can be supported by the large number of clinical trials of mRNA vaccines for various diseases infectious diseases, cancer and rare genetic disorders. The remarkable success of mRNA-based COVID-19 vaccines has not only proven the efficacy & scalability of mRNA technology but also catalysed interest in targeting other therapy areas, such as cancer and rare diseases.
Based on end user, the mRNA synthesis and manufacturing market has been categorized into pharmaceutical and biotechnology companies, academic and research institutes, and CROs and CDMOs. In 2023, pharmaceutical and biotechnology companies dominated the market for mRNA synthesis and manufacturing. According to the market's emerging needs, companies are investing to develop next-generation biologics such as mRNA therapeutics. Higher research and development activities of companies to develop mRNA therapeutics and cell and gene therapies have resulted in rising needs for specialized consumables and instruments as well as synthesis, modification, purification, analysis, and characterization services.
Request Sample Pages:
The global mRNA synthesis and manufacturing market is consolidated with the top five players— Thermo Fisher Scientific Inc. (US), Aldevron, LLC. (Danaher Corporation) (US), TriLink BioTechnologies (US), GenScript (US), and Merck KGaA (Germany). Other prominent market players include, New England Biolabs (US), Promega Corporation (US), Sartorius AG (Germany), WuXi Biologics (China), Takara Bio Inc. (Japan), GENEWIZ (Azenta US, Inc.) (US), Lonza (Switzerland), Telesis Bio Inc. (US), Aurigene Pharmaceutical Services Ltd. (Dr. Reddy's Laboratories Ltd.) (India), ST Pharm (South Korea), AGC Biologics (US).
Thermo Fisher Scientific Inc. (US):
Thermo Fisher Scientific Inc., headquartered in Waltham, Massachusetts, is a leading player in mRNA synthesis and manufacturing, offering a broad range of products and services tailored to this field. The company provides advanced solutions for mRNA synthesis, including custom RNA synthesis services and reagents through its GeneArt platform, which supports the development of mRNA constructs for research, therapeutic, and vaccine applications. Thermo Fisher's technologies enable efficient in vitro transcription (IVT) and include automated solutions that enhance scalability and production efficiency. Their extensive expertise, quality assurance measures, and global reach position them as a key player in advancing mRNA technology and supporting the development of next-generation therapeutics and vaccines.
Aldevron, LLC. (Danaher Corporation) (US):
Aldevron, established in 1998 and based in Fargo, North Dakota, is a key player in the nucleic acid synthesis industry, particularly known for its expertise in mRNA synthesis and manufacturing. The company is highly regarded for producing high-quality mRNA and plasmid DNA, essential for cutting-edge applications in vaccine development, gene therapy, and other biotechnological innovations. Aldevron's offerings include custom RNA synthesis and cGMP-compliant mRNA production, ensuring that their products meet the stringent standards required for clinical use. Aldevron's robust quality control and assurance processes further guarantee the reliability and efficacy of their products. As a global leader in the field, Aldevron has expanded its facilities and technological infrastructure to meet growing demand, establishing a significant presence in the biopharmaceutical sector. Their collaborations with biotechnology firms, pharmaceutical companies, and research institutions underscore their pivotal role in advancing mRNA technology and supporting the development of next-generation therapies and vaccines.
TriLink BioTechnologies (US):
TriLink BioTechnologies, a subsidiary of Maravai LifeSciences based in San Diego, California, is a key player in mRNA synthesis and manufacturing. The company excels in providing high-quality nucleic acid products and services, with a strong focus on mRNA technology. TriLink offers comprehensive mRNA synthesis services, including the production of custom mRNA and chemically modified mRNA, which enhances stability and translation efficiency—crucial for effective therapeutic and vaccine development. Utilizing advanced in vitro transcription technologies, TriLink ensures high yield and purity in their mRNA products.
For more information, Inquire Now!
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.
Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets Inc.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
UK +44-800-368-9399
Visit Our Website: https://www.marketsandmarkets.com/
0 notes
Text
The Phosphoramidite Industry: Trends, Growth, and Market Insights
Market Overview:
The global phosphoramidite market is expected to grow at a compound annual growth rate (CAGR) of 6-8% from 2023 to 2028. Phosphoramidites play a pivotal role in the synthesis of oligonucleotides, which are fundamental in genetic research, diagnostics, and the development of RNA and DNA-based drugs. As the demand for genetic therapies, personalized medicine, and molecular diagnostics rises, the phosphoramidite industry is experiencing substantial growth.
Phosphoramidites are used to introduce specific nucleotides into DNA and RNA sequences during oligonucleotide synthesis. The ability to control this synthesis process with high precision makes phosphoramidites essential for various applications, including PCR (Polymerase Chain Reaction), gene sequencing, gene editing (like CRISPR), and the development of antisense therapies.
Key Market Trends:
Growing Demand for Nucleic Acid-Based Therapies: One of the main drivers of the phosphoramidite market is the increasing development and approval of nucleic acid-based therapies such as antisense oligonucleotides (ASOs), siRNA (small interfering RNA), and mRNA-based vaccines. These therapies are being developed to target various genetic diseases and cancers, with the potential to revolutionize treatments for conditions that are difficult to address with traditional drugs. As a result, there is growing demand for phosphoramidites to synthesize the oligonucleotides used in these therapies.
Advancements in Biotechnology and Genetic Research: The rise of biotechnology and genetic research is a key factor contributing to the growth of the phosphoramidite market. With the increasing use of genetic sequencing, gene synthesis, and CRISPR gene editing technologies, the need for high-quality phosphoramidites in the synthesis of oligonucleotides is on the rise. As these technologies continue to evolve and become more accessible, the demand for phosphoramidites is expected to grow significantly in both research and commercial applications.
Molecular Diagnostics and Personalized Medicine: Molecular diagnostics is another area driving the demand for phosphoramidites. The use of oligonucleotides in the detection of genetic mutations, pathogens, and biomarkers is becoming increasingly important in clinical diagnostics. Personalized medicine, which tailors medical treatment to the individual characteristics of each patient, also depends on the ability to design specific DNA or RNA sequences for targeted therapies. Phosphoramidites are vital in synthesizing the oligonucleotides required for these applications, further boosting market growth.
Increasing Applications in Gene Editing: Gene editing technologies like CRISPR-Cas9 have gained immense popularity for their ability to precisely edit genes in various organisms, including humans. These technologies often rely on oligonucleotides synthesized using phosphoramidites to guide the gene-editing machinery to specific locations in the genome. The rising demand for gene-editing applications in both research and therapeutics is driving the phosphoramidite market, as these oligonucleotides are essential for the success of CRISPR-based applications.
Technological Advancements in Oligonucleotide Synthesis: As the demand for precision and scalability in oligonucleotide synthesis grows, advancements in synthesis technologies are emerging. New methods that increase the efficiency, purity, and yield of oligonucleotide synthesis are driving further growth in the phosphoramidite market. The introduction of automated synthesis platforms, as well as improvements in phosphoramidite production processes, are making it easier to meet the rising demand for high-quality oligonucleotides.
Increasing Investment in Pharmaceutical R&D: The growing investment in pharmaceutical and biotechnology research and development (R&D) activities is driving demand for phosphoramidites. Pharmaceutical companies and academic research institutions are heavily investing in RNA-based therapeutics and gene therapies, which require the synthesis of custom oligonucleotides. As these R&D activities increase, the demand for phosphoramidites used in the synthesis of these specialized nucleic acids is also expected to rise.
Market Segmentation:
The phosphoramidite market can be segmented based on application, end-user, and region.
By Application:
Oligonucleotide Synthesis: The primary application of phosphoramidites, as they are used to build custom DNA and RNA sequences for various research and therapeutic purposes.
Gene Editing and CRISPR Technologies: Phosphoramidites are crucial for the synthesis of oligonucleotides used in gene-editing processes, including CRISPR.
RNA Therapeutics: The development of RNA-based therapies, such as RNA vaccines, antisense oligonucleotides, and siRNA, is a major application for phosphoramidites.
Diagnostics: Used in molecular diagnostic applications, including PCR, gene sequencing, and the detection of genetic disorders or pathogens.
By End-User:
Pharmaceutical and Biotechnology Companies: The largest segment, where phosphoramidites are used for the synthesis of therapeutic oligonucleotides, including antisense oligonucleotides and gene therapies.
Academic and Research Institutions: Universities and research labs are key users of phosphoramidites for genetic research, gene synthesis, and drug discovery.
Diagnostic Laboratories: Laboratories that perform genetic testing and molecular diagnostics are significant consumers of phosphoramidites.
By Region:
North America: Home to leading pharmaceutical and biotechnology companies, North America holds a substantial share of the global phosphoramidite market. The region’s strong emphasis on drug development, gene therapy, and personalized medicine is expected to drive significant demand.
Europe: Europe is another major market for phosphoramidites, driven by advanced research in genomics and biotechnology, as well as increasing demand for molecular diagnostics.
Asia-Pacific: With its rapidly expanding pharmaceutical and biotech sectors, the Asia-Pacific region is witnessing an increase in the demand for phosphoramidites, particularly in China and India.
Rest of the World: Emerging markets in Latin America, the Middle East, and Africa are also growing, although at a slower pace.
Growth Drivers:
Rising Demand for Genetic Therapies and mRNA Vaccines: The COVID-19 pandemic highlighted the importance of mRNA vaccines, and the success of these vaccines has sparked increased interest in mRNA technology for other infectious diseases and even cancer treatments. The ongoing research and development in this space are driving the need for high-quality phosphoramidites for RNA synthesis.
Advancements in Biotechnology and Genetic Research: Continuous innovation in biotechnology, including gene editing and genetic testing, is increasing the need for phosphoramidites. As more industries adopt genetic-based technologies, the demand for reliable and efficient oligonucleotide synthesis will continue to rise.
Government and Private Sector Investments in Biotechnology: Governments and private companies are investing heavily in biotechnology R&D, particularly in the fields of genomics and gene therapy. This investment is creating a strong demand for phosphoramidites, which are essential for these innovative therapeutic approaches.
Personalized Medicine and Precision Healthcare: The rise of personalized medicine, which tailors treatment to an individual’s genetic makeup, is also contributing to the growth of the phosphoramidite market. Oligonucleotides are key tools in the development of personalized medicine, making phosphoramidites a vital component of this emerging healthcare trend.
Challenges Facing the Market:
High Production Costs: The production of phosphoramidites is a complex and costly process. High production costs could limit the widespread adoption of these chemicals in some applications, especially in price-sensitive markets. Companies may face challenges in reducing these costs while maintaining product quality.
Quality Control and Standardization: As the demand for high-quality phosphoramidites increases, maintaining consistent product quality and meeting regulatory standards will be essential. Manufacturers must invest in robust quality control systems to ensure the purity and effectiveness of phosphoramidites used in critical applications like gene therapy and diagnostics.
Intellectual Property and Patent Issues: The increasing focus on nucleic acid-based therapies and gene-editing technologies has led to an increase in intellectual property (IP) concerns and patent disputes. Companies involved in phosphoramidite production may face challenges related to IP rights and patent licensing in the rapidly evolving biotech and pharmaceutical sectors.
Key Players in the Phosphoramidite Market:
Sigma-Aldrich (Merck): A leading supplier of phosphoramidites, with a broad portfolio catering to the synthesis of oligonucleotides and RNA-based therapies.
GE Healthcare Life Sciences: Known for its contributions to molecular diagnostics and gene synthesis, GE Healthcare is a key player in the phosphoramidite market.
BioAutomation Corporation: Specializes in the development of automated oligonucleotide synthesis systems, playing a crucial role in the phosphoramidite supply chain.
Trilink BioTechnologies: A prominent supplier of custom phosphoramidites for DNA and RNA synthesis, including modifications for therapeutic applications.
Fisher Scientific: A global distributor of chemicals, including phosphoramidites, for research and therapeutic applications in the life sciences.
Market Outlook:
The phosphoramidite market is poised for significant growth in the coming years, driven by advancements in biotechnology, personalized medicine, and the increasing adoption of genetic-based therapies. With applications ranging from gene editing and molecular diagnostics to RNA therapeutics, phosphoramidites are essential for the continued innovation in genetic research and therapeutic development. Although challenges such as high production costs and quality control remain, the overall market outlook is optimistic, with substantial opportunities for growth, especially in North America and Europe.
As demand for more precise, targeted therapies and diagnostics continues to rise, the phosphoramidite industry will play an integral role in shaping the future of biotechnology, drug development, and personalized healthcare.
For a detailed overview and more insights, you can refer to the full market research report by Mordor Intelligence
0 notes
global-research-report · 18 days ago
Text
Global Demand for Recombinant Proteins: Market Analysis and Forecast
The global recombinant proteins market size is expected to reach USD 5.58 billion in 2030 and is projected to grow at a CAGR of 10.2% from 2025 to 2030. Diseases like multiple sclerosis, neutropenia, cerebral apoplexy, anemia, and others, as well as dwarfism, are becoming more common, which is driving up the demand for recombinant protein drugs. Furthermore, the industry is anticipated to expand due to the increased development and research on biologics, which, in turn, are significantly boosting global industry growth. The focus on the development of biosimilars, biologics, and recombinant proteins has increased owing to a rise in the incidence and prevalence of cancer and the expansion of research & development activity.
According to the American Cancer Society, in 2022, there will be 1.9 million new cancer cases and 609,360 cancer-related deaths. In addition, the expanding application of recombinant proteins in clinical diagnostic methods including ELISA, Western Blotting, and Immunohistochemistry (IHC) is anticipated to fuel market expansion. Due to factors including rising R&D spending, an increase in the number of cancer patients, and the desire for novel & tailored therapies, the global industry is anticipated to expand significantly during the forecast period. Research activity in recombinant protein space has increased in response to the COVID-19 pandemic as a result of efforts to comprehend the dynamics of the virus. The production of recombinant proteins has increased significantly, along with tailored treatment.
In addition, research funding is predicted to become more readily available along with an increase in demand for and production of recombinant proteins, particularly those immune response proteins associated with COVID-19. Therefore, positive effects have been seen for the companies offering products specifically made for COVID-19. Recombinant protein is viewed as a modified version of natural protein that can be produced in a number of ways to improve protein output, create useful commercial goods, and alter gene sequences. The main drivers of the global industry are the rise in pharmaceutical firms’ R&D expenditures, high incidence of chronic illnesses, an increase in the number of regulatory requirements, and the ongoing need to reduce viral infections.
Over the projected period, the global industry is anticipated to be driven by technological advancements in the synthesis of recombinant proteins. For instance, in June 2022, according to the data produced by the National Center for Biotechnology Information, new breeding techniques, such as CRISPR/Cas9, TALEN, and Zinc Finger mediated, as well as transgenic or cis-genic techniques, are emerging technologies that may make it easier for in vitro genetic editing or manipulation of the genes to be approved. In addition, industry participants are anticipated to invest in the region due to the aging population, rising income levels, better healthcare infrastructure, rising healthcare spending, and the advantages of low-cost manufacturing in developing nations, thereby propelling market growth.
Recombinant Proteins Market Report Highlights
The cytokines & growth factors segment held the largest share of 24.6% of the market in 2024. This segment is anticipated to grow exponentially throughout the forecast period.
The therapeutics segment dominated the global market with a share of 34.2% in 2024 due to the prevalence of various diseases, such as metabolic disorders, cancer, genetic disorders, and immune diseases.
The pharma & biotechnology companies segment captured the largest market share of 38.1% in 2024. The inclination towards biologics and biosimilars has resulted in a cascade of multi-million investments by bio-manufacturers in R&D to grow the pipeline of products, devise new technologies, and advance bioprocessing tools.
The mammalian segment held the largest revenue share of 42.1% of the recombinant proteins market in 2024.
North America was the dominant region in 2024 due to an increase in the incidence of chronic diseases, use of cutting-edge treatments, the presence of key players, and a rise in healthcare spending in the region.
Recombinant Proteins Market Segmentation
Grand View Research has segmented the global recombinant proteins market based on product, application, end use, host cell, and region:
Recombinant Proteins Product Outlook (Revenue, USD Million, 2018 - 2030)
Cytokines & Growth Factors
Interferons (IFNs)
Interleukins (ILs)
Others
Antibodies
Immune checkpoint proteins
Virus Antigens
Enzymes
Kinases
Metabolic enzymes
Others
Recombinant Regulatory Protein
Hormones
Others
Recombinant Proteins Application Outlook (Revenue, USD Million, 2018 - 2030)
Drug Discovery & Development
Therapeutics
Biologics
Vaccines
Cell & Gene Therapies
Others
Research
Others
Recombinant Proteins End Use Outlook (Revenue, USD Million, 2018 - 2030)
Pharma & Biotechnology Companies
Academic & Research Institutes
Diagnostic Laboratories
Others
Recombinant Proteins Host Cell Outlook (Revenue, USD Million, 2018 - 2030)
Mammalian systems
Insect Cells
Yeast & Fungi
Bacterial Cells
Others
Recombinant Proteins Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
US
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
Australia
South Korea
Thailand
Latin America
Brazil
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players
Sino Biological, Inc.
Bio-Techne
GenScript
Bio-Rad Laboratories, Inc.
Merck KGaA
Thermo Fisher Scientific
Proteintech Group, Inc.
Enzo Life Sciences, Inc. 
Abnova Corporation
RayBiotech Life Inc.
STEMCELL Technologies Inc.
Order a free sample PDF of the Recombinant Proteins Market Intelligence Study, published by Grand View Research.
0 notes
ruchinoni · 2 months ago
Text
0 notes